Ailomics Therapeutics is a pharmaceutical R&D startup with a pioneering computational and experimental platform to discover novel targets and develop efficacious therapeutics for the diseases of significant unmet medical needs. Ailomics Therapeutics leverages patients-derived omics data and AI-augmented bioinformatics analytics to deeply understand disease biology and identify the targets that drive disease progressions. Learning from human disease biology, Ailomics Therapeutics develops high-translatability disease models to screen for and optimize functional molecules for therapeutic interventions. The human disease biology insights also enable Ailomics Therapeutics to discover high-precision biomarkers for patient stratification in clinical trials.